Amicus Therapeutics, Inc. (Nasdaq: FOLD) and GlaxoSmithKline (NYSE: GSK) today announced that Amicus has obtained global rights to develop and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE